AR073573A1 - Metodos para utilizar composiciones de aminopiridina de liberacion sostenida - Google Patents
Metodos para utilizar composiciones de aminopiridina de liberacion sostenidaInfo
- Publication number
- AR073573A1 AR073573A1 ARP090103479A ARP090103479A AR073573A1 AR 073573 A1 AR073573 A1 AR 073573A1 AR P090103479 A ARP090103479 A AR P090103479A AR P090103479 A ARP090103479 A AR P090103479A AR 073573 A1 AR073573 A1 AR 073573A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- sustained release
- compositions
- aminopiridine
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 abstract 2
- 229960004979 fampridine Drugs 0.000 abstract 2
- -1 fampridine horn Chemical class 0.000 abstract 2
- 239000002955 immunomodulating agent Substances 0.000 abstract 2
- 229940121354 immunomodulator Drugs 0.000 abstract 2
- 230000002584 immunomodulator Effects 0.000 abstract 2
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010012305 Demyelination Diseases 0.000 abstract 1
- 108010072051 Glatiramer Acetate Proteins 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 abstract 1
- 150000003927 aminopyridines Chemical class 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 229960003776 glatiramer acetate Drugs 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229960005027 natalizumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9579708P | 2008-09-10 | 2008-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073573A1 true AR073573A1 (es) | 2010-11-17 |
Family
ID=41799491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103479A AR073573A1 (es) | 2008-09-10 | 2009-09-10 | Metodos para utilizar composiciones de aminopiridina de liberacion sostenida |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20100061935A1 (enExample) |
| EP (1) | EP2343976A4 (enExample) |
| JP (1) | JP2012502103A (enExample) |
| CN (1) | CN101827522A (enExample) |
| AR (1) | AR073573A1 (enExample) |
| AU (1) | AU2009291781A1 (enExample) |
| BR (1) | BRPI0903914A2 (enExample) |
| CA (1) | CA2736381A1 (enExample) |
| CL (1) | CL2009001841A1 (enExample) |
| PA (1) | PA8841801A1 (enExample) |
| PE (1) | PE20100264A1 (enExample) |
| RU (1) | RU2011113762A (enExample) |
| TW (1) | TW201010703A (enExample) |
| UY (1) | UY32109A (enExample) |
| WO (1) | WO2010030755A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| CA2864340A1 (en) * | 2012-02-13 | 2013-08-22 | Acorda Therapeutics, Inc. | Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine |
| DE102012103179A1 (de) | 2012-04-12 | 2013-10-17 | Sieber Forming Solutions Gmbh | Verfahren und Vorrichtung zur spanlosen Herstellung eines Außengewindes auf Werkstücken aus Metall |
| UY34896A (es) * | 2012-07-12 | 2014-02-28 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina |
| WO2014028387A1 (en) * | 2012-08-13 | 2014-02-20 | Acorda Therapeutics, Inc. | Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine |
| CN104091062A (zh) * | 2014-07-03 | 2014-10-08 | 刘鸿 | 基于检验效能的诊断性试验Meta分析的方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| JP7193448B2 (ja) | 2016-08-31 | 2022-12-20 | マピ ファーマ リミテッド | 酢酸グラチラマーを含むデポシステム |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200462B (enExample) * | 1990-09-27 | 1993-02-21 | Hoechst Roussel Pharma | |
| US6284473B1 (en) * | 1995-10-02 | 2001-09-04 | Uab Research Foundation | P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status |
| WO2004087160A1 (en) * | 2003-04-03 | 2004-10-14 | Prana Biotechnology Ltd | Treatment of neurological conditions |
| EP1651169A4 (en) * | 2003-08-01 | 2008-02-27 | Medarex Inc | POLYTHERAPIES FOR MULTIPLE SCLEROSIS |
| US8354437B2 (en) * | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| EP1888056A4 (en) * | 2005-06-01 | 2008-09-03 | Teva Pharma | USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS |
| EP1940285B1 (en) * | 2005-09-23 | 2019-05-29 | Acorda Therapeutics, Inc. | Method, apparatus and software for identifying responders in a clinical environment |
-
2009
- 2009-09-10 AU AU2009291781A patent/AU2009291781A1/en not_active Abandoned
- 2009-09-10 RU RU2011113762/13A patent/RU2011113762A/ru not_active Application Discontinuation
- 2009-09-10 CN CN200980100162A patent/CN101827522A/zh active Pending
- 2009-09-10 JP JP2011526964A patent/JP2012502103A/ja active Pending
- 2009-09-10 US US12/557,015 patent/US20100061935A1/en not_active Abandoned
- 2009-09-10 AR ARP090103479A patent/AR073573A1/es not_active Application Discontinuation
- 2009-09-10 TW TW098130503A patent/TW201010703A/zh unknown
- 2009-09-10 PE PE2009001123A patent/PE20100264A1/es not_active Application Discontinuation
- 2009-09-10 WO PCT/US2009/056476 patent/WO2010030755A1/en not_active Ceased
- 2009-09-10 CA CA2736381A patent/CA2736381A1/en not_active Abandoned
- 2009-09-10 PA PA20098841801A patent/PA8841801A1/es unknown
- 2009-09-10 BR BRPI0903914-7A patent/BRPI0903914A2/pt not_active Application Discontinuation
- 2009-09-10 CL CL2009001841A patent/CL2009001841A1/es unknown
- 2009-09-10 UY UY0001032109A patent/UY32109A/es not_active Application Discontinuation
- 2009-09-10 EP EP09813589A patent/EP2343976A4/en not_active Withdrawn
-
2012
- 2012-07-05 US US13/542,393 patent/US20130072527A1/en not_active Abandoned
-
2013
- 2013-08-12 US US13/965,171 patent/US20130330277A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101827522A (zh) | 2010-09-08 |
| RU2011113762A (ru) | 2012-10-20 |
| BRPI0903914A2 (pt) | 2015-07-21 |
| US20100061935A1 (en) | 2010-03-11 |
| JP2012502103A (ja) | 2012-01-26 |
| EP2343976A1 (en) | 2011-07-20 |
| AU2009291781A1 (en) | 2010-03-18 |
| PA8841801A1 (es) | 2010-06-28 |
| TW201010703A (en) | 2010-03-16 |
| US20130330277A1 (en) | 2013-12-12 |
| EP2343976A4 (en) | 2011-12-14 |
| CL2009001841A1 (es) | 2011-02-18 |
| WO2010030755A1 (en) | 2010-03-18 |
| CA2736381A1 (en) | 2010-03-18 |
| UY32109A (es) | 2010-04-30 |
| PE20100264A1 (es) | 2010-04-28 |
| US20130072527A1 (en) | 2013-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073573A1 (es) | Metodos para utilizar composiciones de aminopiridina de liberacion sostenida | |
| CY1114298T1 (el) | Διαμορφωτικως περιορισμενα διφαινυλ παραγωγα για χρηση ως αναστολεις ιου ηπατιτιδας c | |
| EA201100795A1 (ru) | Фармацевтическая композиция эффективного ингибитора всг для перорального введения | |
| DK2250163T3 (da) | Hepatitis C-virusinhibitorer | |
| EA200900297A1 (ru) | Ингибиторы вируса гепатита с | |
| CY1117641T1 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
| NO20091846L (no) | Makrocykliske peptider som hepatitt C virus- inhibitorer | |
| NO20075616L (no) | Tripeptider som hepatitt C virus inhibitorer | |
| DK2203430T3 (da) | N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV) | |
| NZ592705A (en) | 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication | |
| DE602007012133D1 (de) | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten | |
| NO20091871L (no) | Hepatitt C virus inhibitorer | |
| MX2012000959A (es) | Inhibidores de los virus flaviviridae. | |
| TN2009000398A1 (en) | 5,6-dihydro-1h-pyridin-2-one compounds | |
| MX2010008699A (es) | Derivados heterociclicos como inhibidores de virus de la hepatitis c. | |
| NZ600817A (en) | Inhibitors of flaviviridae viruses | |
| MX2012008221A (es) | Inhibidores de virus flaviviridae. | |
| EA201491179A1 (ru) | 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с | |
| ATE485304T1 (de) | Muteine von tearlipocalin und verfahren zu deren gewinnung | |
| CA2753382C (en) | Hepatitis c virus inhibitors | |
| ES2531009T3 (es) | Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos | |
| CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
| CY1112653T1 (el) | Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης | |
| EA200970805A1 (ru) | Ингибиторы серинпротеаз для лечения hcv инфекций | |
| EA200901289A1 (ru) | Композиции и способы для противовосполительного лечения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |